PMID- 35630804
OWN - NLM
STAT- MEDLINE
DCOM- 20220531
LR  - 20220716
IS  - 1420-3049 (Electronic)
IS  - 1420-3049 (Linking)
VI  - 27
IP  - 10
DP  - 2022 May 22
TI  - Cannabidiol Improves Antioxidant Capacity and Reduces Inflammation in the Lungs 
      of Rats with Monocrotaline-Induced Pulmonary Hypertension.
LID - 10.3390/molecules27103327 [doi]
LID - 3327
AB  - Cannabidiol (CBD) is a plant-derived compound with antioxidant and 
      anti-inflammatory properties. Pulmonary hypertension (PH) is still an incurable 
      disease. CBD has been suggested to ameliorate monocrotaline (MCT)-induced PH, 
      including reduction in right ventricular systolic pressure (RVSP), a vasorelaxant 
      effect on pulmonary arteries and a decrease in the white blood cell count. The 
      aim of our study was to investigate the effect of chronic administration of CBD 
      (10 mg/kg daily for 21 days) on the parameters of oxidative stress and 
      inflammation in the lungs of rats with MCT-induced PH. In MCT-induced PH, we 
      found a decrease in total antioxidant capacity (TAC) and glutathione level (GSH), 
      an increase in inflammatory parameters, e.g., tumor necrosis factor alpha 
      (TNF-alpha), interleukin-1beta (IL-1beta), nuclear factor kappa B (NF-kappaB), monocyte 
      chemoattractant protein-1 (MCP-1), and cluster of differentiation 68 (CD68), and 
      the overexpression of cannabinoid receptors type 1 and 2 (CB(1)-Rs, CB(2)-Rs). 
      Administration of CBD increased TAC and GSH concentrations, glutathione reductase 
      (GSR) activity, and decreased CB(1)-Rs expression and levels of inflammatory 
      mediators such as TNF-alpha, IL -1beta, NF-kappaB, MCP-1 and CD68. In conclusion, CBD has 
      antioxidant and anti-inflammatory effects in MCT-induced PH. CBD may act as an 
      adjuvant therapy for PH, but further detailed preclinical and clinical studies 
      are recommended to confirm our promising results.
FAU - Krzyzewska, Anna
AU  - Krzyzewska A
AUID- ORCID: 0000-0001-5986-3757
AD  - Department of Experimental Physiology and Pathophysiology, Medical University of 
      Bialystok, Mickiewicz 2A, 15-222 Bialystok, Poland.
FAU - Baranowska-Kuczko, Marta
AU  - Baranowska-Kuczko M
AUID- ORCID: 0000-0002-7238-2656
AD  - Department of Experimental Physiology and Pathophysiology, Medical University of 
      Bialystok, Mickiewicz 2A, 15-222 Bialystok, Poland.
AD  - Department of Clinical Pharmacy, Medical University of Bialystok, Mickiewicz 2A, 
      15-222 Bialystok, Poland.
FAU - Jastrzab, Anna
AU  - Jastrzab A
AUID- ORCID: 0000-0002-5766-6271
AD  - Department of Analytical Chemistry, Medical University of Bialystok, Mickiewicz 
      2D, 15-222 Bialystok, Poland.
FAU - Kasacka, Irena
AU  - Kasacka I
AUID- ORCID: 0000-0003-2954-942X
AD  - Department of Histology and Cytophysiology, Medical University of Bialystok, 
      Mickiewicz 2C, 15-222 Bialystok, Poland.
FAU - Kozlowska, Hanna
AU  - Kozlowska H
AUID- ORCID: 0000-0002-2105-3350
AD  - Department of Experimental Physiology and Pathophysiology, Medical University of 
      Bialystok, Mickiewicz 2A, 15-222 Bialystok, Poland.
LA  - eng
GR  - SUB/1/DN/22/001/2213/Medical University of Bialystok/
PT  - Journal Article
DEP - 20220522
PL  - Switzerland
TA  - Molecules
JT  - Molecules (Basel, Switzerland)
JID - 100964009
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antioxidants)
RN  - 0 (NF-kappa B)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 19GBJ60SN5 (Cannabidiol)
RN  - 73077K8HYV (Monocrotaline)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacology
MH  - Antioxidants/metabolism
MH  - *Cannabidiol/pharmacology
MH  - *Hypertension, Pulmonary/chemically induced/drug therapy
MH  - Inflammation/chemically induced/drug therapy
MH  - Lung/pathology
MH  - Monocrotaline
MH  - NF-kappa B/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Tumor Necrosis Factor-alpha/metabolism
PMC - PMC9143935
OTO - NOTNLM
OT  - cannabidiol
OT  - inflammation
OT  - monocrotaline
OT  - oxidative stress
OT  - pulmonary hypertension
COIS- The authors declare no conflict of interest.
EDAT- 2022/05/29 06:00
MHDA- 2022/06/01 06:00
PMCR- 2022/05/22
CRDT- 2022/05/28 01:35
PHST- 2022/04/28 00:00 [received]
PHST- 2022/05/19 00:00 [revised]
PHST- 2022/05/20 00:00 [accepted]
PHST- 2022/05/28 01:35 [entrez]
PHST- 2022/05/29 06:00 [pubmed]
PHST- 2022/06/01 06:00 [medline]
PHST- 2022/05/22 00:00 [pmc-release]
AID - molecules27103327 [pii]
AID - molecules-27-03327 [pii]
AID - 10.3390/molecules27103327 [doi]
PST - epublish
SO  - Molecules. 2022 May 22;27(10):3327. doi: 10.3390/molecules27103327.